Vascular endothelial growth factor overexpression is correlated with von Hippel‐Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma
Open Access
- 28 June 2002
- Vol. 95 (1), 47-53
- https://doi.org/10.1002/cncr.10635
Abstract
A high frequency of genetic alterations of the von Hippel-Lindau (VHL) gene and overexpression of the vascular endothelial growth factor (VEGF) gene have been observed independently in human sporadic renal cell carcinoma (RCCs), but to the authors' knowledge the association between the two has not been characterized in primary sporadic RCC. In the current study the authors report the simultaneous comparison of the biallelic inactivation status of the VHL gene and VEGF expression levels in patients with sporadic RCC. DNA and RNA were extracted from 27 sporadic RCC samples. Mutation was analyzed by direct sequencing of the amplified VHL DNA and cDNA. Loss of heterozygosity (LOH) of the gene was analyzed at three polymorphic markers. The VEGF mRNA was measured using Northern blot analysis. Mutations of the VHL gene were found in 14 of 27 RCC samples (51.9%). LOH analysis by a VHL-intragenic polymorphic marker and 2 extragenic microsatellite markers, D3S1560 and D3S1317, showed that LOH occurred in 10 of 15 RCC samples (66.7%). Overexpression of VEGF mRNA was observed in 17 of 27 RCC cases (63.0%): 15 of the 18 RCC samples estimated to have at least 1 hit, but only 2 of the 6 RCC samples with 0-1 hit, and none of the 3 RCC samples in which the VHL gene was not inactivated. VEGF overexpression was found to be correlated with both monoallelic and biallelic VHL inactivation. Alteration of the VHL gene is believed to cause angiogenesis in RCC cases through the overexpression of VEGF. Cancer 2002;95:47–53. © 2002 American Cancer Society. DOI 10.1002/cncr.10635Keywords
This publication has 23 references indexed in Scilit:
- BIALLELIC INACTIVATION OF THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR GENE IN SPORADIC RENAL CELL CARCINOMAJournal of Urology, 2002
- Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau proteinNature Cell Biology, 2000
- CHARACTERISTIC LOSS OF HETEROZYGOSITY IN CHROMOSOME 3P AND LOW FREQUENCY OF REPLICATION ERRORS IN SPORADIC RENAL CELL CARCINOMAJournal of Urology, 1999
- Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCCHuman Mutation, 1999
- The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysisNature, 1999
- Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin LigaseScience, 1999
- Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor FunctionScience, 1999
- The von Hippel-Lindau Tumor Suppressor Gene Product Interacts with Sp1 To Repress Vascular Endothelial Growth Factor Promoter ActivityMolecular and Cellular Biology, 1997
- Somatic mutations of the von Hippel — Lindau disease tumour suppressor gene in non-familial clear cell renal carcinomaHuman Molecular Genetics, 1994
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993